Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Beyondspring Inc (BYSI)

Beyondspring Inc (BYSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed Nov 12, 6:00AM CST

Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with...

BYSI : 1.9900 (+3.11%)
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment GlobeNewswire - Wed Aug 13, 7:00AM CDT

ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med  (Cell Press) Publication with MD Anderson Collaboration...

BYSI : 1.9900 (+3.11%)
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure GlobeNewswire - Mon Jul 7, 6:00AM CDT

BYSI : 1.9900 (+3.11%)
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors BayStreet.ca - Thu Jun 12, 9:16AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The future of cancer research appears to be drifting away from the public sector to the private sector,...

ONCY : 0.9921 (+1.16%)
BYSI : 1.9900 (+3.11%)
ELEV : 0.3650 (-2.12%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.9200 (+5.49%)
CRDF : 2.11 (-2.31%)
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting GlobeNewswire - Tue Jun 3, 6:00AM CDT

BYSI : 1.9900 (+3.11%)
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting GlobeNewswire - Wed May 28, 6:00AM CDT

BYSI : 1.9900 (+3.11%)
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Mon May 12, 3:30PM CDT

BYSI : 1.9900 (+3.11%)
BeyondSpring Files 2024 Annual Report on Form 10-K GlobeNewswire - Thu Mar 27, 6:05AM CDT

BYSI : 1.9900 (+3.11%)
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones GlobeNewswire - Thu Mar 27, 6:00AM CDT

BYSI : 1.9900 (+3.11%)
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies GlobeNewswire - Tue Jan 28, 6:00AM CST

BYSI : 1.9900 (+3.11%)

Barchart Exclusives

Most “Safe” Dividend Stocks Don’t Grow Like This… But These 3 Did Barchart - Fri Dec 5, 6:00PM CST
Three Dividend Kings Wall Street rates “Strong Buy”, supported by strong five-year earnings growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot